The parent of a child who wore the device to manage diabetes described failed alerts and inaccurate readings in a complaint.

DexCom, Inc. (NASDAQ:DXCM) is one of the best growth stocks to buy and hold forever. On September 22, UBS reiterated a ‘Buy’ rating on the stock and a $106 price target. The research firm reiterated ...

Investing.com - UBS maintained its Buy rating and $106.00 price target on DexCom (NASDAQ:DXCM) following a Friday sell-off triggered by concerns about the company’s G7 continuous glucose monitoring ...

Earlier this year, while speaking with Fierce Medtech at the annual J.P. Morgan Healthcare Conference, Dexcom CEO Kevin Sayer noted that the continuous glucose monitor maker had recently changed its ...

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. The FDA approves ...